CA Patent

CA3094449C — Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases

Assigned to Ascentage Pharma Suzhou Co Ltd · Expires 2023-02-28 · 3y expired

What this patent protects

Provided herein is a combination product comprising a Bcl-2 inhibitor and an MDM-2 inhibitor, the combination product providing a use in the prevention and/or treatment of diseases (e.g., cancer).

USPTO Abstract

Provided herein is a combination product comprising a Bcl-2 inhibitor and an MDM-2 inhibitor, the combination product providing a use in the prevention and/or treatment of diseases (e.g., cancer).

Drugs covered by this patent

Patent Metadata

Patent number
CA3094449C
Jurisdiction
CA
Classification
—
Expires
2023-02-28
Drug substance claim
No
Drug product claim
No
Assignee
Ascentage Pharma Suzhou Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.